

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HealthyWay Inc.
健康之路股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2587)

**CHANGE OF NON-EXECUTIVE DIRECTOR AND CHANGE IN THE
COMPOSITION OF BOARD COMMITTEES**

The board (the “**Board**”) of directors (the “**Directors**”) of HealthyWay Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces the following changes in the composition of the Board:

Resignation of Non-Executive Director

The Board announces that Mr. Zhang Xiangming has tendered his resignation as a non-executive Director with effect from 10 June 2026 to devote more time to his personal endeavours. Following his resignation, Mr. Zhang will also cease to be a member of each of the audit committee, the remuneration committee and the nomination committee of the Company with effect from 10 June 2026.

Mr. Zhang has confirmed that he has no disagreement with the Board, and there are no other matters in relation to his resignation that need to be brought to the attention of the shareholders of the Company.

The Board would like to express its sincere gratitude to Mr. Zhang for his valuable contribution to the Company during his tenure of office.

Appointment of Non-Executive Director

The Board is pleased to announce that Mr. Wang Junfeng (王俊峰) (“**Mr. Wang**”) has been appointed as a non-executive Director, and as a member of each of the audit committee, the remuneration committee and the nomination committee of the Company, with effect from 10 June 2026.

Biographical Details

Mr. Wang, aged 39, has over 10 years of experience in the technology industry, with a particular focus on artificial intelligence and healthcare technology. He has been working at Baidu Online Network Technology (Beijing) Co., Ltd. (百度在線網路技術(北京)有限公司) since August 2013, and currently serves as the head of Baidu’s health technology businesses. He is also the chairman of Baidu’s health technology committee and a member of Baidu’s technology ethics committee. During his tenure at Baidu, Mr. Wang has led his team in the development and application of artificial intelligence technologies and has received internal recognition for his contributions to technology innovation. He also has published a number of academic papers in the field of artificial intelligence at international conferences.

Mr. Wang obtained a master’s degree in Computer Science and Technology from Zhejiang University.

Mr. Wang has entered into a letter of appointment with the Company for a fixed term of three years commencing 10 June 2026 and shall continue thereafter unless and until it is terminated in accordance with their respective terms. He is subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the Articles of Association. Pursuant to the said letter of appointment, Mr. Wang will not receive any emoluments for his role as a Director.

Baidu Online Network Technology (Beijing) Co., Ltd. is a subsidiary of Baidu, Inc., a company listed on the Stock Exchange (stock code: 9888.HK). As at the date of this announcement, Baidu, Inc., through its subsidiary Baidu (Hong Kong) Limited, owns approximately 10.96% of the total issued shares of the Company; hence, is a substantial shareholder of the Company. Save as disclosed above, as at the date of this announcement, Mr. Wang (i) does not have any relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company; (ii) does not have any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong); (iii) does not hold any other position with the Company or any member of the Group; and (iv) has not held any directorship in any other listed public companies in Hong Kong or overseas in the last three years.

The Board is not aware of any other matters relating to the appointment of Mr. Wang that need to be brought to the attention of the shareholders of the Company, nor is there any information required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board would like to extend its warm welcome to Mr. Wang on his appointment.

On behalf of the Board
HealthyWay Inc.
Zhang Wanneng
*Chairman of the Board, Executive Director
and Chief Executive Officer*

Fuzhou, the PRC, 10 June 2026

As at the date of this announcement, the Board comprises Mr. Zhang Wanneng and Mr. Chen Jing as executive directors; Mr. Wang Junfeng as non-executive director; and Mr. Xu Jing, Dr. Lu Tao and Ms. Deng Xiaolan as independent non-executive directors.